Response to Office communication dated: 5/24/2005

Attorney Docket: UCONAP/141/US

Please amend the claims as follows:

1-22. cancelled

23. (currently amended) The A-method of claim 28 wherein the compound is inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a compound represented by the following structural formula and physiologically acceptable salts thereof

$$AA - C - NH - C_2H_5, AA - C - NH OH AA - C - O - C_4H_2OH$$

$$AA - C - O - C - OH AA - C - NH OH AA - C - NH OH$$

$$AA - C - NH - C_2H_5, AA - C - NH - OH$$

$$AA - C - NH - OH$$

Response to Office communication dated: 5/24/2005

Attorney Docket: UCONAP/141/US

24. (currently amended) The method of claim <u>28</u> 23 wherein the compound is represented by the following structural formula and physiologically acceptable salts thereof:

$$AA - C - NH - C_2H_5, \quad AA - C - NH \qquad OH \qquad AA - C - O - C_4H_2OH$$

$$AA - C - O - C \qquad OH \qquad AA - C - O \qquad OH \qquad AA - C - N \qquad OH$$

$$AA - C - N \qquad OH \qquad AA - C - N \qquad OH$$

$$AA - C - N \qquad OH \qquad AA - C - N \qquad OH$$

$$AA - C - N \qquad OH \qquad AA - C - NH \qquad OH$$

$$2,2-dimethyl-AA - C - NH \qquad OH$$

$$2,2-dimethyl-AA - C - NH \qquad OH$$

25. (currently amended) The method of claim <u>28</u> 23 wherein the compound is represented by the following structural formula and physiologically acceptable salts thereof:

Response to Office communication dated: 5/24/2005

Attorney Docket: UCONAP/141/US

26. cancelled

27. (currently amended) A method of inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a compound represented by the following structural formula and physiologically acceptable salts thereof:

Response to Office communication dated: 5/24/2005

Attorney Docket: UCONAP/141/US

28. (new) A method of inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a compound represented by the following structural formula and physiologically acceptable salts thereof

AA
$$\longrightarrow$$
 C \longrightarrow NH \longrightarrow C₂H₅ AA \longrightarrow C \longrightarrow NH₂ AA \longrightarrow C \longrightarrow OH \longrightarrow AA \longrightarrow C \longrightarrow OH \longrightarrow 2,2-dimethyl-AA \longrightarrow C \longrightarrow NH \longrightarrow OH \longrightarrow OH